Diabetes mellitus E14.90

Author: Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 02.11.2026

Dieser Artikel auf Deutsch

Synonym(s)

Diabetes

Definition
This section has been translated automatically.

Diabetes mellitus is a metabolic disease. It is caused by a chronically elevated blood sugar level and insulin resistance or insulin deficiency in the body. The disease is usually associated with severe concomitant and secondary diseases.

Classification
This section has been translated automatically.

Type 1 diabetes (about 5 %): beta-cell destruction leads to insulin deficiency. This form can occur due to immunological factors. A special form is LADA (latent autoimmune diabetes), in which the disease spreads slowly in adulthood.
In addition, type 1 diabetes can occur idiopathically (rare in Europe).

Type 2 diabetes(about 90%): Type 2 diabetes is influenced by three factors: insulin resistance, secretory defect of B and A cells and progressive apoptosis of B cells.

Other forms of diabetes:

  • Genetic defects in beta-cell function: MODY (Maturity-onset diabetes of the young): manifestation before the age of 25 (circa 1%); includes 11 forms.
  • Genetic defects of insulin action
  • Diseases of the exocrine pancreas
  • Endocrinopathies: glucagonomic, Cushing's syndrome, hyperthyroid aldosteronomic, acromegaly, pheochromocytoma
  • Drug-induced: thyroid hormones, hormonal contraceptives, glucocorticoids, betaadrenergics, thiazides
  • Infections: CMV infection, congenital rubella infection
  • Genetic syndromes associated with diabetes: Down syndrome, Klinefelter syndrome, Turner syndrome
  • Rare immunological forms such as anti-insulin receptor antibodies

Occurrence/Epidemiology
This section has been translated automatically.

The prevalence of manifest diabetics depends on age, but has increased significantly in the last 3 years: < 50 years = 1 to 2 %, > 60 years = about 10 %, > 70 years up to 20 %.

Clinic
This section has been translated automatically.

Manifest diabetes mellitus:

While the development to type 1 diabetes is relatively fast, type 2 diabetes manifests itself rather slowly and unnoticed. The following symptoms may occur:

Non-specific general symptoms: Fatigue, reduced performance

Symptoms due to electrolyte and fluid balance disorders: Calf cramps and visual disturbances

Skin symptoms: Pruritus, bacterial skin infections, rubeosis diabetica, necrobiosis lipoidicaPotency disorders
, amenorrhoea

symptoms due to hyperglycaemia and glucosuria with osmotic diuresis: thirst, weight loss, polyuria, polydipsia

Laboratory
This section has been translated automatically.

Blood sugar determination, determination of glucose in urine, determination of ketone bodies, oral glucose tolerance test (OGTT), continuous measurement of blood sugar level over 72 hours, diagnosis of gestational diabetes, screening for diabetes mellitus, HbA1c

Diagnosis
This section has been translated automatically.

A diagnosis is made on the basis of a medical history, the clinical picture and laboratory tests

Complication(s)(associated diseases
This section has been translated automatically.

Macro-/microangiopathy, diabetic cariomyopathy, reduced resistance with a tendency to bacterial skin and urinary tract infections, fatty liver, lipid metabolism disorder, hyporeninemic hypoaldosteronism, coma diabeticum (hypoglycemic shock).

For patients with diabetes mellitus (type 1 and 2), the probability of contracting herpes zoster increases by up to 38%. For patients with type 2 diabetes, the risk almost doubles. If patients with diabetes mellitus develop herpes zoster, they have a 45% increased risk of post-herpes zoster neuralgia (Poirrier JE et al. 2022).

Therapy
This section has been translated automatically.

It is recommended that you diet or reduce your weight within the BMI to a normal level. In addition, physical activity should be increased and medication should be prescribed. Patients should take prophylaxis and therapy of possible complications and other risk factors, this is also possible by means of training.

Complementary medical therapy methods
This section has been translated automatically.

Studies also indicate the importance of the gut microbiome— and specifically dysbiosis—in both the development and persistence of type 2 diabetes mellitus. Microbial diversity is reduced, particularly among bacteria that produce short-chain fatty acids, whereas an increase in Gram-negative bacteria that produce endotoxins has been reported (Mendis BILM et al. 2025). Changes in the gut microbiome have also been observed in insulin resistance (Wu H et al. 2020).

Studies involving the administration of specific microbiota(see also “Microbiological Therapy”) provide initial evidence of a potential treatment option for insulin resistance and diabetes (Roden M 2021). See also “Insulin Resistance.”

See also under “Gut Microbiome” and “Diabetes Mellitus Type 2.” 

Studies indicate changes in the gut microbiome in insulin resistance, as in diabetes mellitus (Wu H et al. 2020). Furthermore, the administration of specific microbiota has been shown to be a potential treatment option for insulin resistance and diabetes (Roden M 2021).

In dysbiosis, the production of short-chain fatty acids is inhibited, leading to a reduction in the release of incretins—which include glucagon-like peptide—resulting in insulin resistance and type 2 diabetes. Glucagon-like peptide is secreted by the intestinal mucosa upon food intake and stimulates insulin secretion while inhibiting glucagon secretion in the pancreas, simultaneously increasing insulin sensitivity and causing a centrally regulated reduction in appetite.

In the gut microbiome, certain bacteria, such as Lactobacillus reuteri and Akkermansia muciniphila, stimulate the secretion of glucagon-like peptide in the gut and thus counteract insulin resistance, prediabetes, and diabetes. 

In a randomized, double-blind, prospective 4-week study, the secretion of incretins such as glucagon-like peptide, as well as insulin levels, was monitored in non-diabetics. Consumption of the lactic acid-producing bacterium Lactobacillus reuteri increased glucagon-like peptide secretion by 76% and insulin secretion by 50% (Roden M 2021).

Note(s)
This section has been translated automatically.

See also: Gut-Brain Axis.

Literature
This section has been translated automatically.

  1. Poirrier JE et al. (2022) Herpes Zoster Incidence and Burden in Adults With Type 2 Diabetes in the U.S.: A Retrospective Database Analysis. Diabetes Care 45:2585–2593.
  2. Bielka W et al. (2022) The Role of the Gut Microbiota in the Pathogenesis of Diabetes. Int J Mol Sci 1;23(1):480. doi: 10.3390/ijms23010480. PMID: 35008906; PMCID: PMC8745411.
  3. Mendis BILM et al. (2025) Mechanisms and key mediators of gut microbiota and type 2 diabetes mellitus: A comprehensive overview,
  4. Medicine in Microecology, 26, 100144. ISSN 2590-0978, https://doi.org/10.1016/j.medmic.2025.100144.
  5. Roden M (2021) Modulation of incretin secretion by probiotics and diet – Werner-Creutzfeldt Prize 2021. Diabetology and Metabolism; 16(06): 465–466. DOI: 10.1055/a-1664-5096
  6. Wu H et al. (2020) The Gut Microbiota in Prediabetes and Diabetes: A Population-Based Cross-Sectional Study. Cell Metab 1;32(3):379–390.e3. doi: 10.1016/j.cmet.2020.06.011. Epub 2020 Jul 10. PMID: 32652044.

Disclaimer

Please ask your physician for a reliable diagnosis. This website is only meant as a reference.

Authors

Last updated on: 02.11.2026